寡转移性乳腺癌的立体定向放疗研究进展

doi:10.3760/cma.j.cn113030-20200224-00071

Abstract
Figure/Table
References(51)
Related Citation (15)
Read Tracking
Download Tracking

Download: PDF (0 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS) Supporting Info

Abstract Distant metastasis is the leading cause of death for breast cancer patients, and advanced metastatic breast cancer is mainly considered incurable. Oligometastasis is an"intermediate stage" between local primary tumor and extensive metastasis. As a local treatment approach, radiotherapy plays an important role in the management of oligometastatic breast cancer. The development of stereotactic body radiotherapy (SBRT) allows the delivery of ablative doses to the targets without exceeding the dose constraints of organs-at-risk. Studies have shown that SBRT is safe and effective, with local control rates of more than 80% for breast cancer oligometastasis to the bone, lung, liver, brain, and lymph nodes. However, how to screen the true oligometastasis remains controversial. Randomized clinical trials will be essential to confirm whether SBRT can improve the survival outcomes.

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	Song Yuchun
	Wang Shulian

Key words： Neoplasm oligometastasis, breast/stereotactic body radiotherapy Research progress

Received: 24 February 2020

Corresponding Authors: Wang Shulian, Email:wsl20040118@yahoo.com

Cite this article:

Song Yuchun,Wang Shulian. Research progress on stereotactic body radiotherapy for oligometastatic breast cancer[J]. Chinese Journal of Radiation Oncology, 2021, 30(11): 1221-1225.

URL:

http://journal12.magtechjournal.com/Jweb_fszlx/EN/10.3760/cma.j.cn113030-20200224-00071 OR http://journal12.magtechjournal.com/Jweb_fszlx/EN/Y2021/V30/I11/1221

[1] Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015[J]. CA Cancer J Clin, 2016, 66(2):115-132. DOI:10.3322/caac.21338.
[2] Early Breast Cancer Trialists' Collaborative G. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival:an overview of the randomised trials[J]. Lancet, 2005, 365(9472):1687-1717. DOI:10.1016/S0140-6736(05)66544-0.
[3] Hellman S,Weichselbaum RR. Oligometastases[J]. J Clin Oncol, 1995, 13(1):8-10. DOI:10.1200/JCO.1995.13.1.8.
[4] Pagani O, Senkus E, Wood W, et al. International guidelines for management of metastatic breast cancer:can metastatic breast cancer be cured?[J]. J Natl Cancer Inst, 2010, 102(7):456-463. DOI:10.1093/jnci/djq029.
[5] Van Cutsem E, Cervantes A, Adam R, et al. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer[J]. Ann Oncol, 2016, 27(8):1386-1422. DOI:10.1093/annonc/mdw235.
[6] Allard MA, Adam R, Giuliante F, et al. Long-term outcomes of patients with 10 or more colorectal liver metastases[J]. Br J Cancer, 2017, 117(5):604-611. DOI:10.1038/bjc.2017.218.
[7] Pawlik TM, Abdalla EK, Ellis LM, et al. Debunking dogma:surgery for four or more colorectal liver metastases is justified[J]. J Gastrointest Surg, 2006, 10(2):240-248. DOI:10.1016/j.gassur.2005.07.027.
[8] Tsai MS, Su YH, Ho MC, et al. Clinicopathological features and prognosis in resectable synchronous and metachronous colorectal liver metastasis[J]. Ann Surg Oncol, 2007, 14(2):786-794. DOI:10.1245/s10434-006-9215-5.
[9] Friedel G, Pastorino U, Ginsberg RJ, et al. Results of lung metastasectomy from breast cancer:prognostic criteria on the basis of 467 cases of the International Registry of Lung Metastases[J]. Eur J Cardiothorac Surg, 2002, 22(3):335-344. DOI:10.1016/s1010-7940(02)00331-7.
[10] De Giorgi U, Valero V, Rohren E, et al. Circulating tumor cells and bone metastases as detected by FDG-PET/CT in patients with metastatic breast cancer[J]. Ann Oncol, 2010, 21(1):33-39. DOI:10.1093/annonc/mdp262.
[11] Lussier YA, Xing HR, Salama JK, et al. MicroRNA expression characterizes oligometastasis (es)[J]. PLoS One, 2011, 6(12):e28650. DOI:10.1371/journal.pone.0028650.
[12] Guckenberger M, Lievens Y, Bouma AB, et al. Characterisation and classification of oligometastatic disease:a European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendation[J]. Lancet Oncol, 2020, 21(1):e18-e28. DOI:10.1016/s1470-2045(19)30718-1.
[13] Potters L, Kavanagh B, Galvin JM, et al. American Society for Therapeutic Radiology and Oncology (ASTRO) and American College of Radiology (ACR) practice guideline for the performance of stereotactic body radiation therapy[J]. Int J Radiat Oncol Biol Phys, 2010, 76(2):326-332. DOI:10.1016/j.ijrobp.2009.09.042.
[14] Demaria S, Golden EB,Formenti SC. Role of local radiation therapy in cancer immunotherapy[J]. JAMA Oncol, 2015, 1(9):1325-1332. DOI:10.1001/jamaoncol.2015.2756.
[15] Chen Z, Moyana T, Saxena A, et al. Efficient antitumor immunity derived from maturation of dendritic cells that had phagocytosed apoptotic/necrotic tumor cells[J]. Int J Cancer, 2001, 93(4):539-548. DOI:10.1002/ijc.1365.
[16] Lotze MT, Zeh HJ, Rubartelli A, et al. The grateful dead:damage-associated molecular pattern molecules and reduction/oxidation regulate immunity[J]. Immunol Rev, 2007, 220:60-81. DOI:10.1111/j.1600-065X.2007.00579.x.
[17] Park HJ, Griffin RJ, Hui S, et al. Radiation-induced vascular damage in tumors:implications of vascular damage in ablative hypofractionated radiotherapy (SBRT and SRS)[J]. Radiat Res, 2012, 177(3):311-327. DOI:10.1667/rr2773.1.
[18] Mole RH. Whole body irradiation;radiobiology or medicine?[J]. Br J Radiol, 1953, 26(305):234-241. DOI:10.1259/0007-1285-26-305-234.
[19] Postow MA, Callahan MK, Barker CA, et al. Immunologic correlates of the abscopal effect in a patient with melanoma[J]. N Engl J Med, 2012, 366(10):925-931. DOI:10.1056/NEJMoa1112824.
[20] Gomez DR, Blumenschein GR, Jr., Lee JJ, et al. Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy:a multicentre, randomised, controlled, phase 2 study[J]. Lancet Oncol, 2016, 17(12):1672-1682. DOI:10.1016/S1470-2045(16)30532-0.
[21] Antonia SJ, Villegas A, Daniel D, et al. Durvalumab after chemoradiotherapy in stage Ⅲ non-small-cell lung cancer[J]. New Engl J Med, 2017, 377(20):1919-1929. DOI:10.1056/NEJMoa1709937.
[22] Palma DA, Olson R, Harrow S, et al. Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET):a randomised, phase 2, open-label trial[J]. Lancet, 2019, 393(10185):2051-2058. DOI:10.1016/S0140-6736(18)32487-5.
[23] Brooks ED,Chang JY. Time to abandon single-site irradiation for inducing abscopal effects[J]. Nat Rev Clin Oncol, 2019, 16(2):123-135. DOI:10.1038/s41571-018-0119-7.
[24] Ganss R, Ryschich E, Klar E, et al. Combination of T-cell therapy and trigger of inflammation induces remodeling of the vasculature and tumor eradication[J]. Cancer Res, 2002, 62(5):1462-1470. DOI:10.1046/j.1523-5394.2002.102010.x.
[25] Heppner GH,Shekhar M. Tumor heterogeneity is fundamental to the tumor ecosystem[J]. Oncology (Williston Park), 2014, 28(9):780-781.
[26] Coleman RE. Metastatic bone disease:clinical features, pathophysiology and treatment strategies[J]. Cancer Treat Rev, 2001, 27(3):165-176. DOI:10.1053/ctrv.2000.0210.
[27] Largillier R, Ferrero JM, Doyen J, et al. Prognostic factors in 1,038 women with metastatic breast cancer[J]. Ann Oncol, 2008, 19(12):2012-2019. DOI:10.1093/annonc/mdn424.
[28] Milano MT, Katz AW, Zhang H, et al. Oligometastases Treated With Stereotactic Body Radiotherapy:long-term follow-up of prospective study[J]. Int J Radiat Oncol Biol Phys, 2012, 83(3):878-886. DOI:10.1016/j.ijrobp.2011.08.036.
[29] Gerszten PC, Burton SA, Welch WC, et al. Single-fraction radiosurgery for the treatment of spinal breast metastases[J]. Cancer, 2005, 104(10):2244-2254. DOI:10.1002/cncr.21467.
[30] Ahmed KA, Stauder MC, Miller RC, et al. Stereotactic body radiation therapy in spinal metastases[J]. Int J Radiat Oncol Biol Phys, 2012, 82(5):e803-e809. DOI:10.1016/j.ijrobp.2011.11.036.
[31] Ryu S, Pugh SL, Gerszten PC, et al. RTOG 0631 phase2/3 study of image guided stereotactic radiosurgery for localized (1-3) spine metastases:phase 2 results[J]. Pract Radiat Oncol, 2014, 4(2):76-81. DOI:10.1016/j.prro.2013.05.001.
[32] Bedard G, McDonald R, Poon I, et al. Stereotactic body radiation therapy for non-spine bone metastases-a review of the literature[J]. Ann Palliat Med, 2016, 5(1):58-66. DOI:10.3978/j.issn.2224-5820.2015.07.01.
[33] Yoo GS, Yu JI, Park W, et al. Prognostic factors in breast cancer with extracranial oligometastases and the appropriate role of radiation therapy[J]. Radiat Oncol J, 2015, 33(4):301-309. DOI:10.3857/roj.2015.33.4.301.
[34] Staren ED, Salerno C, Rongione A, et al. Pulmonary resection for metastatic breast cancer[J]. Arch Surg, 1992, 127(11):1282-1284. DOI:10.1001/archsurg.1992.01420110024006.
[35] Yoshimoto M, Tada K, Nishimura S, et al. Favourable long-term results after surgical removal of lung metastases of breast cancer[J]. Breast Cancer Res Treat, 2008, 110(3):485-491. DOI:10.1007/s10549-007-9747-9.
[36] Rusthoven KE, Kavanagh BD, Burri SH, et al. Multi-institutional phase Ⅰ/Ⅱ trial of stereotactic body radiation therapy for lung metastases[J]. J Clin Oncol, 2009, 27(10):1579-1584. DOI:10.1200/JCO.2008.19.6386.
[37] Singh D, Chen Y, Hare MZ, et al. Local control rates with five-fraction stereotactic body radiotherapy for oligometastatic cancer to the lung[J]. J Thorac Dis, 2014, 6(4):369-374. DOI:10.3978/j.issn.2072-1439.2013.12.03.
[38] Rusthoven KE, Kavanagh BD, Cardenes H, et al. Multi-institutional phase Ⅰ/Ⅱ trial of stereotactic body radiation therapy for liver metastases[J]. J Clin Oncol, 2009, 27(10):1572-1578. DOI:10.1200/JCO.2008.19.6329.
[39] Onal C, Guler OC,Yildirim BA. Treatment outcomes of breast cancer liver metastasis treated with stereotactic body radiotherapy[J]. Breast, 2018, 42:150-156. DOI:10.1016/j.breast.2018.09.006.
[40] Mahadevan A, Blanck O, Lanciano R, et al. Stereotactic body radiotherapy (SBRT) for liver metastasis–clinical outcomes from the international multi-institutional RSSearch^® patient registry[J]. Radiat Oncol, 2018, 13(1):26. DOI:10.1186/s13014-018-0969-2.
[41] Swaminath A, Massey C, Brierley JD, et al. Accumulated delivered dose response of stereotactic body radiation therapy for liver metastases[J]. Int J Radiat Oncol Biol Phys, 2015, 93(3):639-648. DOI:10.1016/j.ijrobp.2015.07.2273.
[42] Chidel MA, Suh JH, Reddy CA, et al. Application of recursive partitioning analysis and evaluation of the use of whole brain radiation among patients treated with stereotactic radiosurgery for newly diagnosed brain metastases[J]. Int J Radiat Oncol Biol Phys, 2000, 47(4):993-999. DOI:10.1016/s0360-3016(00)00527-7.
[43] Kirkpatrick JP, Wang Z, Sampson JH, et al. Defining the optimal planning target volume in image-guided stereotactic radiosurgery of brain metastases:results of a randomized trial[J]. Int J Radiat Oncol Biol Phys, 2015, 91(1):100-108. DOI:10.1016/j.ijrobp.2014.09.004.
[44] Casamassima F, Livi L, Masciullo S, et al. Stereotactic radiotherapy for adrenal gland metastases:university of Florence experience[J]. Int J Radiat Oncol Biol Phys, 2012, 82(2):919-923. DOI:10.1016/j.ijrobp.2010.11.060.
[45] Jereczek-Fossa BA, Ronchi S, Orecchia R. Is stereotactic body radiotherapy (SBRT) in lymph node oligometastatic patients feasible and effective?[J]. Rep Pract Oncol Radiother, 2015, 20(6):472-483. DOI:10.1016/j.rpor.2014.10.004.
[46] Yeung R, Hamm J, Liu M, et al. Institutional analysis of stereotactic body radiotherapy (SBRT) for oligometastatic lymph node metastases[J]. Radiat Oncol, 2017, 12(1):105. DOI:10.1186/s13014-017-0820-1.
[47] Franzese C, Fogliata A, Comito T, et al. Stereotactic/hypofractionated body radiation therapy as an effective treatment for lymph node metastases from colorectal cancer:an institutional retrospective analysis[J]. Br J Radiol, 2017, 90(1079):20170422. DOI:10.1259/bjr.20170422.
[48] Matsushita H, Jingu K, Umezawa R, et al. Stereotactic radiotherapy for oligometastases in lymph nodes-a review[J]. Technol Cancer Res Treat, 2018, 17:1533033818803597-1533033818803597. DOI:10.1177/1533033818803597.
[49] Benedict SH, Yenice KM, Followill D, et al. Stereotactic body radiation therapy:the report of AAPM Task Group 101[J]. Med Phys, 2010, 37(8):4078-4101. DOI:10.1118/1.3438081.
[50] Stinauer MA, Kavanagh BD, Schefter TE, et al. Stereotactic body radiation therapy for melanoma and renal cell carcinoma:impact of single fraction equivalent dose on local control[J]. Radiat Oncol, 2011, 6:34. DOI:10.1186/1748-717X-6-34.
[51] Hanna GG, Murray L, Patel R, et al. UK consensus on normal tissue dose constraints for stereotactic radiotherapy[J]. Clin Oncol, 2018, 30(1):5-14. DOI:10.1016/j.clon.2017.09.007.